A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors

Conditions

• Tumours, Gynecological

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Mo-Rez — DRUG
  Mo-Rez will be administered intravenously (IV).
• Dostarlimab — DRUG
  Dostarlimab will be administered IV.
• Bevacizumab — DRUG
  Bevacizumab will be administered IV.

Study Details

Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.

Key Dates

Start date

Mar 4, 2025

Status verified

May 2026

Primary completion

Jun 21, 2027

Completion

Oct 10, 2028

Study Design

Enrollment

305 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Module 1 (Mo-Rez +Dostarlimab) Endometrial Cancer
• Experimental: Module 2 (Mo-Rez +/-Bevacizumab) Ovarian Cancer

Primary Outcome Measure

Part A: Percentage of participants with dose limiting toxicities (DLTs) [ Time Frame: Approximately 7 months ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (4)

Find similar trials in La Jolla, CA